Dr. Reddy’s unveils generic of Solu-Medrol
The Hindu
HYDERABAD
Dr. Reddy’s Laboratories has unveiled Methylprednisolone Sodium Succinate for Injection, USP, its generic equivalent of Solu-Medrol, in the U.S. market.
The product, launched following the U.S. Food and Drug Administration (USFDA) approval, is indicated for various conditions, including arthritis, blood disorders, allergic reactions and certain cancers.
A trademark of Pharmacia & Upjohn Company LLC, Solu-Medrol brand and generic had U.S. sales of approximately $144 million MAT for the most recent 12 months ended in February 2022, Dr. Reddy’s said, citing IQVIA Health numbers.
The company said its Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial, 125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.